Floyd Bloom - Alkermes Plc Independent Director
| ALKS Stock | USD 24.05 0.19 0.80% |
Director
Dr. Floyd E. Bloom M.D. is Independent Director of the Company. Dr. Bloom was a founder of Alkermes, Inc. and was active in neuropharmacology for more than 35 years, holding positions at Yale University, the National Institute of Mental Health, The Salk Institute, and The Scripps Research Institute. From 1983 to February 2005, Dr. Bloom was the Chairman of the Neuropharmacology Department at The Scripps Research Institute and is now Professor Emeritus. Dr. Bloom served as EditorinChief of Science from 1995 to May 2000. He is a member of the National Academy of Sciences, the Royal Swedish Academy of Science and the American Philosophical Society. He is an Emeritus Trustee for the Board of Trustees at Washington University in St. Louis. Dr. Bloom is a director of AgeneBio, Inc. a privately held biopharmaceutical company. Dr. Bloom also serves on the Scientific Advisory Boards of aTyr Pharma, a privately held pharmaceutical company, RiverVest, a private venture partnership focusing on life sciences, and Interpreta Inc., a privately held analytics service company, and as chairman of the Scientific Board for ModGene Pharma LLC, a privately held research and development company. Dr. Bloom served as a member of the board of directors of Elan from 2007 to 2009. since 2011.
| Age | 80 |
| Tenure | 13 years |
| Professional Marks | Ph.D |
| Address | Connaught House, Dublin, Ireland, D04 C5Y6 |
| Phone | 353 1 772 8000 |
| Web | https://www.alkermes.com |
Alkermes Plc Management Efficiency
The company has return on total asset (ROA) of 0.1465 % which means that it generated a profit of $0.1465 on every $100 spent on assets. This is way below average. Similarly, it shows a return on stockholder's equity (ROE) of 0.5045 %, meaning that it created $0.5045 on every $100 dollars invested by stockholders. Alkermes Plc's management efficiency ratios could be used to measure how well Alkermes Plc manages its routine affairs as well as how well it operates its assets and liabilities. Return On Tangible Assets is likely to gain to 0.18 in 2024. Return On Capital Employed is likely to gain to 0.27 in 2024. At this time, Alkermes Plc's Total Assets are comparatively stable compared to the past year. Non Currrent Assets Other is likely to gain to about 165.2 M in 2024, whereas Other Assets are likely to drop 0.95 in 2024.Similar Executives
| Showing other executives | DIRECTOR Age | ||
| George Conrades | Ironwood Pharmaceuticals | 76 | |
| Douglas Braunstein | Eagle Pharmaceuticals | 57 | |
| Meredith Kaya | Ironwood Pharmaceuticals | N/A | |
| Ravi Bhoothalingam | Dr Reddys Laboratories | 68 | |
| Simone Blank | Evolus Inc | 55 | |
| Paul Hastings | Pacira Pharmaceuticals | 58 | |
| Gerald Carlson | Phibro Animal Health | 75 | |
| Liam Ratcliffe | Deciphera Pharmaceuticals LLC | 53 | |
| Bruce Carter | Dr Reddys Laboratories | 77 | |
| John Martin | Deciphera Pharmaceuticals LLC | 57 | |
| Peggy Phillips | Dynavax Technologies | 64 | |
| Laura Brege | Dynavax Technologies | 60 | |
| Celeste Clark | Prestige Brand Holdings | 67 | |
| Hans Hasler | Dr Reddys Laboratories | 60 | |
| Michael Zasloff | Amphastar P | 72 | |
| Dan Kisner | Dynavax Technologies | 67 | |
| Stephen Shohet | Amphastar P | 82 | |
| David Pernock | Eagle Pharmaceuticals | 63 | |
| Eran Nadav | Collegium Pharmaceutical | 45 | |
| Patrick Heron | Collegium Pharmaceutical | 44 | |
| John Byom | Prestige Brand Holdings | 66 | |
Management Performance
Alkermes Plc Leadership Team
Elected by the shareholders, the Alkermes Plc's board of directors comprises two types of representatives: Alkermes Plc inside directors who are chosen from within the company, and outside directors, selected externally and held independent of Alkermes. The board's role is to monitor Alkermes Plc's management team and ensure that shareholders' interests are well served. Alkermes Plc's inside directors are responsible for reviewing and approving budgets prepared by upper management to implement core corporate initiatives and projects. On the other hand, Alkermes Plc's outside directors are responsible for providing unbiased perspectives on the board's policies.
| Peter Norman, Senior Relations | ||
| David Gaffin, Senior Vice President Chief Legal Officer | ||
| Richard Pops, Chairman and CEO | ||
| Iain Brown, Chief Accounting Officer | ||
| Craig Hopkinson, Senior Vice President - Clinical Development and Medical Affairs, Chief Medical Officer | ||
| Gordon Pugh, COO, Senior Vice President Chief Risk Officer | ||
| Nancy Snyderman, Director | ||
| Declan OConnor, Health Environment | ||
| James Robinson, COO | ||
| Michael Landine, Senior Vice President - Corporate Development | ||
| Thomas Harvey, Chief IT | ||
| James Frates, CFO, Sr. VP and Treasurer | ||
| Craig MD, Executive Officer | ||
| Floyd MD, Founder | ||
| Nancy Wysenski, Director | ||
| Mark Stejbach, Senior Vice President Chief Commercial Officer | ||
| Shane Cooke, President | ||
| Sandra Coombs, Senior Relations | ||
| Mark Namchuk, Senior Vice President - Research, Pharmaceutical and Non-Clinical Development | ||
| Rebecca Peterson, Senior Vice President | ||
| Floyd Bloom, Independent Director | ||
| Kathryn Biberstein, Chief Compliance Officer, Chief Legal Officer, Sr. VP and Secretary | ||
| Robert Breyer, Independent Director | ||
| Wendy Dixon, Independent Director | ||
| Blair Jackson, Executive Officer | ||
| David Anstice, Independent Director | ||
| Paul Mitchell, Lead Independent Director | ||
| Elliot Ehrich, Senior Vice President - Research and Development, Chief Medical Officer | ||
| Samuel Parisi, Interim Finance | ||
| CTodd Nichols, Senior Vice President of Sales and Marketing | ||
| Stephen Schiavo, Senior Resources |
Alkermes Stock Performance Indicators
The ability to make a profit is the ultimate goal of any investor. But to identify the right stock is not an easy task. Is Alkermes Plc a good investment? Although profit is still the single most important financial element of any organization, multiple performance indicators can help investors identify the equity that they will appreciate over time.
| Return On Equity | 0.5 | ||||
| Return On Asset | 0.15 | ||||
| Profit Margin | 0.25 % | ||||
| Operating Margin | 0.12 % | ||||
| Current Valuation | 3.52 B | ||||
| Shares Outstanding | 169.22 M | ||||
| Shares Owned By Insiders | 1.24 % | ||||
| Shares Owned By Institutions | 98.76 % | ||||
| Number Of Shares Shorted | 13.52 M | ||||
| Price To Earning | (38.45) X |
Alkermes Plc Investors Sentiment
The influence of Alkermes Plc's investor sentiment on the probability of its price appreciation or decline could be a good factor in your decision-making process regarding taking a position in Alkermes. The overall investor sentiment generally increases the direction of a stock movement in a one-year investment horizon. However, the impact of investor sentiment on the entire stock market does not have solid backing from leading economists and market statisticians.
Investor biases related to Alkermes Plc's public news can be used to forecast risks associated with an investment in Alkermes. The trend in average sentiment can be used to explain how an investor holding Alkermes can time the market purely based on public headlines and social activities around Alkermes Plc. Please note that most equities that are difficult to arbitrage are affected by market sentiment the most.
Alkermes Plc's market sentiment shows the aggregated news analyzed to detect positive and negative mentions from the text and comments. The data is normalized to provide daily scores for Alkermes Plc's and other traded tickers. The bigger the bubble, the more accurate is the estimated score. Higher bars for a given day show more participation in the average Alkermes Plc's news discussions. The higher the estimated score, the more favorable is the investor's outlook on Alkermes Plc.
Some investors attempt to determine whether the market's mood is bullish or bearish by monitoring changes in market sentiment. Unlike more traditional methods such as technical analysis, investor sentiment usually refers to the aggregate attitude towards Alkermes Plc in the overall investment community. So, suppose investors can accurately measure the market's sentiment. In that case, they can use it for their benefit. For example, some tools to gauge market sentiment could be utilized using contrarian indexes, Alkermes Plc's short interest history, or implied volatility extrapolated from Alkermes Plc options trading.
Pair Trading with Alkermes Plc
One of the main advantages of trading using pair correlations is that every trade hedges away some risk. Because there are two separate transactions required, even if Alkermes Plc position performs unexpectedly, the other equity can make up some of the losses. Pair trading also minimizes risk from directional movements in the market. For example, if an entire industry or sector drops because of unexpected headlines, the short position in Alkermes Plc will appreciate offsetting losses from the drop in the long position's value.Moving together with Alkermes Stock
| 0.82 | VRAX | Virax Biolabs Group Fiscal Year End 12th of June 2024 | PairCorr |
Moving against Alkermes Stock
| 0.58 | INDP | Indaptus Therapeutics Financial Report 9th of May 2024 | PairCorr |
| 0.54 | LIXT | Lixte Biotechnology Earnings Call This Week | PairCorr |
| 0.44 | ELVN | Enliven Therapeutics Trending | PairCorr |
The ability to find closely correlated positions to Alkermes Plc could be a great tool in your tax-loss harvesting strategies, allowing investors a quick way to find a similar-enough asset to replace Alkermes Plc when you sell it. If you don't do this, your portfolio allocation will be skewed against your target asset allocation. So, investors can't just sell and buy back Alkermes Plc - that would be a violation of the tax code under the "wash sale" rule, and this is why you need to find a similar enough asset and use the proceeds from selling Alkermes Plc to buy it.
The correlation of Alkermes Plc is a statistical measure of how it moves in relation to other instruments. This measure is expressed in what is known as the correlation coefficient, which ranges between -1 and +1. A perfect positive correlation (i.e., a correlation coefficient of +1) implies that as Alkermes Plc moves, either up or down, the other security will move in the same direction. Alternatively, perfect negative correlation means that if Alkermes Plc moves in either direction, the perfectly negatively correlated security will move in the opposite direction. If the correlation is 0, the equities are not correlated; they are entirely random. A correlation greater than 0.8 is generally described as strong, whereas a correlation less than 0.5 is generally considered weak.
Correlation analysis and pair trading evaluation for Alkermes Plc can also be used as hedging techniques within a particular sector or industry or even over random equities to generate a better risk-adjusted return on your portfolios.Check out Trending Equities to better understand how to build diversified portfolios, which includes a position in Alkermes Plc. Also, note that the market value of any company could be tightly coupled with the direction of predictive economic indicators such as signals in industry. For more information on how to buy Alkermes Stock please use our How to Invest in Alkermes Plc guide.You can also try the Alpha Finder module to use alpha and beta coefficients to find investment opportunities after accounting for the risk.
Complementary Tools for Alkermes Stock analysis
When running Alkermes Plc's price analysis, check to measure Alkermes Plc's market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy Alkermes Plc is operating at the current time. Most of Alkermes Plc's value examination focuses on studying past and present price action to predict the probability of Alkermes Plc's future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move Alkermes Plc's price. Additionally, you may evaluate how the addition of Alkermes Plc to your portfolios can decrease your overall portfolio volatility.
| Companies Directory Evaluate performance of over 100,000 Stocks, Funds, and ETFs against different fundamentals | |
| Fundamental Analysis View fundamental data based on most recent published financial statements | |
| Equity Analysis Research over 250,000 global equities including funds, stocks and ETFs to find investment opportunities | |
| Earnings Calls Check upcoming earnings announcements updated hourly across public exchanges | |
| Portfolio File Import Quickly import all of your third-party portfolios from your local drive in csv format | |
| Portfolio Suggestion Get suggestions outside of your existing asset allocation including your own model portfolios | |
| Funds Screener Find actively-traded funds from around the world traded on over 30 global exchanges |
Is Alkermes Plc's industry expected to grow? Or is there an opportunity to expand the business' product line in the future? Factors like these will boost the valuation of Alkermes Plc. If investors know Alkermes will grow in the future, the company's valuation will be higher. The financial industry is built on trying to define current growth potential and future valuation accurately. All the valuation information about Alkermes Plc listed above have to be considered, but the key to understanding future value is determining which factors weigh more heavily than others.
Earnings Share 3.06 | Revenue Per Share 10.34 | Quarterly Revenue Growth 0.218 | Return On Assets 0.1465 | Return On Equity 0.5045 |
The market value of Alkermes Plc is measured differently than its book value, which is the value of Alkermes that is recorded on the company's balance sheet. Investors also form their own opinion of Alkermes Plc's value that differs from its market value or its book value, called intrinsic value, which is Alkermes Plc's true underlying value. Investors use various methods to calculate intrinsic value and buy a stock when its market value falls below its intrinsic value. Because Alkermes Plc's market value can be influenced by many factors that don't directly affect Alkermes Plc's underlying business (such as a pandemic or basic market pessimism), market value can vary widely from intrinsic value.
Please note, there is a significant difference between Alkermes Plc's value and its price as these two are different measures arrived at by different means. Investors typically determine if Alkermes Plc is a good investment by looking at such factors as earnings, sales, fundamental and technical indicators, competition as well as analyst projections. However, Alkermes Plc's price is the amount at which it trades on the open market and represents the number that a seller and buyer find agreeable to each party.